VPC
PASG icon

Vestal Point Capital’s Passage Bio PASG Stock Holding History

Vestal Point Capital’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-305,000
Closed -$2.39M – 86
2026
Q1 		$2.39M Hold
305,000
– – 0.07% 84
2025
Q4 		$3.6M Hold
305,000
– – 0.12% 66
2025
Q3 		$2.45M Hold
305,000
– – 0.11% 75
2025
Q2 		$2.44M Hold
305,000
– – 0.13% 61
2025
Q1 		$2.15M Hold
305,000
– – 0.15% 53
2024
Q4 		$3.46M Hold
305,000
– – 0.21% 60
2024
Q3 		$4.27M Buy
305,000
+2,400
+0.8% +$38.2K 0.32% 51
2024
Q2 		$4.81M Buy
302,600
+77,600
+34% +$1.9M 0.36% 44
2024
Q1 		$6.08M Buy
+225,000
New +$5.41M 0.5% 39

Other funds holding PASG

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $291M AUM 19.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM

Vestal Point Capital's PASG Position: Q2 2026 in Review

Vestal Point Capital sold out of Passage Bio (PASG) in Q2 2026, closing a stake of 305,000 shares — an estimated $2.39M sold.

Vestal Point Capital first reported a position in PASG in Q1 2024 and held it in 9 quarters. The position peaked at $6.08M in Q1 2024. 30 funds tracked by Wall St. Rank hold PASG as of Q2 2026.

  • Vestal Point Capital reported no remaining Passage Bio position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 305,000 Passage Bio shares in Q2 2026, an estimated $2.39M.
  • Vestal Point Capital first reported a position in Passage Bio in Q1 2024 and held it in 9 quarters.
  • Vestal Point Capital's Passage Bio position peaked at $6.08M in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Passage Bio as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.